We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-19.08%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
378
Reduced
937
Closed
183
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$6.27M |
| 2 |
TJX Companies
TJX
|
+$5.89M |
| 3 |
General Mills
GIS
|
+$5.87M |
| 4 |
HP
HPQ
|
+$5.84M |
| 5 |
Ford
F
|
+$5.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$16.7M |
| 2 |
Amazon
AMZN
|
+$14.9M |
| 3 |
Iron Mountain
IRM
|
+$14.6M |
| 4 |
Microsoft
MSFT
|
+$12.9M |
| 5 |
GDS Holdings
GDS
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.6% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1176
Vale
VALE
$62.6B
| $82K | ﹤0.01% |
4,699
+1,766
| +60% | +$30.8K |
|
|
GTHX
1177
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $81K | ﹤0.01% |
3,366
-710
| -17% | -$16.5K |
|
|
DCPH
1178
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $81K | ﹤0.01% |
1,798
-428
| -19% | -$19.9K |
|
|
DVAX
1179
DELISTED
Dynavax Technologies
DVAX
| $80K | ﹤0.01% |
8,133
-10,642
| -57% | -$87.7K |
|
|
EXAS
1180
DELISTED
Exact Sciences
EXAS
| $80K | ﹤0.01% |
604
-415
| -41% | -$56.8K |
|
1181
United Microelectronic
UMC
$43.6B
| $80K | ﹤0.01% |
8,749
+3,586
| +69% | +$33.2K |
|
1182
Veracyte
VCYT
$4.44B
| $80K | ﹤0.01% |
1,488
-720
| -33% | -$41.5K |
|
1183
CareDx
CDNA
$1.85B
| $79K | ﹤0.01% |
1,154
-758
| -40% | -$58.9K |
|
1184
Cytokinetics
CYTK
$10.8B
| $79K | ﹤0.01% |
3,417
-2,214
| -39% | -$47.3K |
|
1185
Agios Pharmaceuticals
AGIO
$2.14B
| $78K | ﹤0.01% |
1,504
-2,420
| -62% | -$120K |
|
1186
Alnylam Pharmaceuticals
ALNY
$38.5B
| $78K | ﹤0.01% |
550
-472
| -46% | -$71K |
|
1187
Neurocrine Biosciences
NBIX
$18.4B
| $78K | ﹤0.01% |
799
-656
| -45% | -$68.8K |
|
|
KRTX
1188
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $78K | ﹤0.01% |
650
-340
| -34% | -$38.5K |
|
|
FPRX
1189
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $78K | ﹤0.01% |
2,062
+1,164
| +130% | +$29K |
|
1190
BioMarin Pharmaceuticals
BMRN
$12B
| $77K | ﹤0.01% |
1,019
-646
| -39% | -$52.8K |
|
|
KYNB
1191
Kyntra Bio
KYNB
$28.2M
| $77K | ﹤0.01% |
88
-41
| -32% | -$43.7K |
|
1192
Ironwood Pharmaceuticals
IRWD
$626M
| $77K | ﹤0.01% |
6,889
-2,506
| -27% | -$26.5K |
|
1193
Madrigal Pharmaceuticals
MDGL
$12.4B
| $77K | ﹤0.01% |
656
-330
| -33% | -$38.5K |
|
1194
MannKind Corp
MNKD
$1.21B
| $77K | ﹤0.01% |
19,748
+9,020
| +84% | +$37K |
|
1195
uniQure
QURE
$2.52B
| $77K | ﹤0.01% |
2,296
+224
| +11% | +$8.03K |
|
|
XLRN
1196
DELISTED
Acceleron Pharma
XLRN
| $77K | ﹤0.01% |
568
-492
| -46% | -$63.6K |
|
1197
iShares Core MSCI Emerging Markets ETF
IEMG
$147B
| $76K | ﹤0.01% |
+1,185
| New | +$78K |
|
1198
Myriad Genetics
MYGN
$502M
| $76K | ﹤0.01% |
2,510
-396
| -14% | -$11.2K |
|
1199
Natera
NTRA
$36.1B
| $76K | ﹤0.01% |
744
-618
| -45% | -$67.7K |
|
1200
Syndax Pharmaceuticals
SNDX
$1.74B
| $76K | ﹤0.01% |
3,402
+866
| +34% | +$19.6K |
|
Similar funds
SAM
Pacer Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Pacer Advisors held 1,587 positions worth $5.75B, up 8.1% from $5.32B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pacer Advisors withdrew a net $1.1B in Q1 2021, closing 183 positions and reducing 937 holdings. Its most notable exit was Rithm Capital, an estimated $4.39M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pacer Advisors opened a new position in Aerojet Rocketdyne Holdings worth $3.39M.
- Pacer Advisors's largest Q1 2021 buy was Aerojet Rocketdyne Holdings: 72,150 shares worth $3.39M.
- Pacer Advisors added most to Newmont in Q1 2021, an estimated $6.27M increase.
- Pacer Advisors's biggest Q1 2021 reduction was Apple, cutting an estimated $16.7M.
- Pacer Advisors fully exited Rithm Capital in Q1 2021, selling an estimated $4.39M.
- Pacer Advisors's ten largest holdings make up 27% of its $5.75B portfolio in Q1 2021.
- Pacer Advisors opened 76 new positions and closed 183 in Q1 2021.
- Pacer Advisors's portfolio value rose 8.1% quarter-over-quarter to $5.75B.
Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.